Compare BMEZ & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMEZ | FLGT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.9M | 867.4M |
| IPO Year | N/A | 2016 |
| Metric | BMEZ | FLGT |
|---|---|---|
| Price | $15.24 | $26.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | ★ 391.3K | 206.0K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | ★ $315,549,000.00 |
| Revenue This Year | N/A | $16.84 |
| Revenue Next Year | N/A | $9.74 |
| P/E Ratio | $30.17 | ★ N/A |
| Revenue Growth | N/A | ★ 13.61 |
| 52 Week Low | $12.93 | $14.57 |
| 52 Week High | $16.95 | $31.04 |
| Indicator | BMEZ | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 42.88 |
| Support Level | $14.92 | $26.63 |
| Resistance Level | $15.28 | $28.26 |
| Average True Range (ATR) | 0.19 | 0.62 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 51.30 | 4.59 |
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.